Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 9/20 | 0.46 |
| ▸ | F13A1 | P00488 | 6/20 | 0.46 |
| ▸ | TGM1 | P22735 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253618 | 0.90 | SMN1; SMN2 (0.46) | USP2SMN1; SMN2MAPTL3MBTL1GAA | |
| SCHEMBL23487527 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL16415215 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL5717360 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL4551353 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2GAATGM2F13A1 | |
| SCHEMBL2251415 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2MAPTTGM2F13A1 | |
| SCHEMBL26113743 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2TGM2F13A1TGM1 | |
| SCHEMBL25470758 | 0.85 | L3MBTL1 (0.46) | USP2SMN1; SMN2MAPTPOLBNPSR1 | |
| SCHEMBL7527689 | 0.85 | USP2 (0.42) | USP2SMN1; SMN2GAATGM2F13A1 | |
| Hydrochloric Acid SCHEMBL12501570 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2TGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| CN-109311880-B | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3759075-A1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | Ferro Therapeutics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102822165-A | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2012-12-12 | — | — | CN | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | USP2 1295/4885SMN1; SMN2 2416/4885MAPT 4231/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | USP2 2895/4885SMN1; SMN2 3696/4885MAPT 619/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | USP2 2895/4885SMN1; SMN2 3696/4885MAPT 619/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | USP2 2895/4885SMN1; SMN2 3696/4885MAPT 619/4885 |
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | USP2 1165/4885SMN1; SMN2 3305/4885MAPT 2307/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | USP2 1187/4885SMN1; SMN2 3391/4885MAPT 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.